Population Pharmacokinetics/Toxicodynamics (PK/TD) Relationship of SAM486A in Phase I Studies in Patients with Advanced Cancers

Journal of Clinical Pharmacology

Volumn 40, Issue 3, 2000, Pages 275-283

  Zhou, Honghui ^a   Choi, Les ^a   Lau, Henry ^a   Bruntsch, Ute ^b   De Vries, Elisabeth E G E ^c   Eckhardt, Gail ^d   Van Oosterom, A T ^e   Verweij, Jaap ^f   Schran, Horst ^a   Barbet, Nicholas ^a   Linnartz, Ronald ^a   Capdeville, Renaud ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Medizinische Klinik   (Germany)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMIDINO 1 INDANONE 2' AMIDINOHYDRAZONE; 4-AMIDINOINDAN-1-ONE 2'-AMIDINOHYDRAZONE; AMIDINE; ANTINEOPLASTIC AGENT; INDAN DERIVATIVE;

ADULT; ARTICLE; BIOLOGICAL MODEL; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; NEUTROPENIA; NEUTROPHIL; PATHOLOGY; PHASE 1 CLINICAL TRIAL;

ADULT; AMIDINES; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDANS; INFUSIONS, INTRAVENOUS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; NEUTROPENIA; NEUTROPHILS;

EID: 0034146546     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022008946     Document Type: Article

References (24)

1. Porter CW, Regenass U, Bergeron RJ: Polyamine inhibitors and analogues as potential anticancer agents, in: Dowling RH, Fölsch UR, Löser R (eds.), Polyamines in the gastrointestinal tract: Falk Symposium, 62 ed. Dordrecht, the Netherlands: Kluwer, 1992;301-322.
2. McCann PP, Pegg AE: Ornithine decarboxylase as an enzyme target for therapy. Pharmacol Ther 1992;54:195-215.
3. Pegg AE, McCann PP: S-adenosylmethionine decarboxylase as an enzyme target for therapy. Pharmacol Ther 1992;56:359-377.
4. Regenass U, Caravatti G, Mett H, Stanek J, Schneider P, Muller M, Matter A, Vertino P, Porter CW: New S-adenosylmethionine decarboxylase inhibitors with potent antitumor activity. Cancer Res 1992; 52(17):4712-4718.
5. Warrell RP, Burchenal JH: Methylgloxal-bis(guanylhydrazone) (Methyl-GAG): current status and future prospects. J Clin Oncol 1983;1:52-65.
6. Dorhout B, Te Velde RJ, Ferwerda H, Kingma AW, de Hoog E, Muskiet FA: In vivo effects of 4-amidinoindan-1-one 2′-amidinohydrazone (CGP 48664A) and alpha-difluromethylornithine (DFMO) on L1210 growth, cell-cycle phase distribution and polyamine contents. Int J Cancer 1995;62:738-742.
7. Regenass U, Mett H, Stanek J, Muller M, Kramer D, Porter CW: CGP 48664, an S-adenosylmethionine decarboxylase inhibitor with broad antiproliferative and anti-tumor activity. Cancer Res 1994;54: 3210-3217.
8. Gutman M, Beltran PJ, Fan D, Delworth M, Singh RK, Wilson M, Fidler IJ: Treatment of nude mice with 4-amidinoindanon-1-(2′-amidino)hydrazone, a new S-adenosylmethionine decarboxylase inhibitor, delays growth and inhibits metastasis of human melanoma cells. Melanoma Res 1995;5:147-155.
9. Delworth MG, Nishioka K, Pettaway C, Gutman M, Killion JJ, Von Eschenbach AC, Fidler IJ: Systemic administration of 4-amidinoindanon-1-(2′-amidino)-hydrazone, a new inhibitor of S-adenosylmethionine decarboxylase, produces cytostasis of human prostate cancer in athymic nude mice. Int J Oncol 1997;6:293-299.
10. Dorhout B, Te Velde RJ, Ferwerda H, Kingma AW, De Hoog E, Muskiet FAJ: In vivo growth inhibition of L1210 leukemia by 4-amidinoindan-1-one 2′amidinohydrazone (CGP 48664), a new inhibitor of S-adenosylmethionine decarboxylase. Int J Carcer 1995; 61:214-217.
11. Greim G, Bruntsch U, Eskens F, Hoppener F, Barbet NC, Choi L, Hanauske AR, Verweij J: Phase I and pharmacologic study of CGP 48664, a SAMDC inhibitor, given once weekly × 4 in patients with solid tumors. American Society of Clinical Oncology 34th Annual Meeting Proceedings 1998;17:232a.
12. Siu LL, Rowinski EK, Weiss GR, Hammond L, Kraynak M, Moczygemba J, Choi L, Barbet NC, DeMoor C, Von Hoff DD, Eckhardt SG: A phase I and pharmacokinetic (PK) study of the polyamine biosynthesis inhibitor CGP 48664 in patients with advanced cancer. American Society of Clinical Oncology 34th Annual Meeting Proceedings 1998;17:191a.
13. Paridaens R, Uges DRA, Barbet N, Seeghers M, Van der Graaf WTA, Lassus M, Groen HJM, Dumez H, Muskiet F, Man A, Van Oosterom AT, De Vries EGE: Phase I dose escalation and pharmacokinetic study of CGP 48664, a new S-adenosylmethionine decarboxylase (SAMDC) inhibitor, administered in continuous infusion over 5 days in cancer patients with solid tumors. American Society of Clinical Oncology 34th Annual Meeting Proceedings 1998;17:190a.
14. Degen PH, Zbinden P: Automated quantitative determination of a new polyamine biosynthesis inhibitor (CGP 48664) and a potential metabolite in human and in animal plasma by high-performance liquid chromatography. J Chromatogr 1996;681:339-345.
15. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175.
16. Nusbaum NJ, Abraham T: Paclitaxel effect on a leukemia cell line: importance of paclitaxel concentration. Anticancer Drugs 1995; 6(3):427-431.
17. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G, Egorin MJ: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13(1):180-190.
18. Duffull SB, Robinson BA: Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 1997;33(3):161-183.
19. Beijnen JH, Huizing MT, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Giaccone G, Pinedo HM: Bioanalysis, pharmacokinetics, and pharmacodynamics of novel anticancer drug paclitxel (Taxol). Semin Oncol 1994;21(5, Suppl. B):53-62.
20. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV: Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994;12(3):532-538.
21. Coleman CN, Halsey J, Cox RS, Hirst VK, Blaschke T, Howes AE, Wasserman TH, Urtasun RC, Pajak T, Hancock S, et al: Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile. Cancer Res 1987;47(1):319-322.
22. Millward MJ, Newell DR, Yuen K, Matthews JP, Balmanno K, Charlton CJ, Gumbrell L, Lind MJ, Chapman F, Proctor M, et al: Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. Cancer Chemother Pharmacol 1995;37(1-2):161-167.
23. Piantadosi S, Liu G: Improved designs for dose escalation studies using pharmacokinetic measurements. Stat Med 1996;15(15):1605-1618.
24. Karlsson MO, Molnar V, Bergh J, Freijs A, Larsson R: A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 1998;63(1):11-25.